scholarly journals The effects of canagliflozin compared to sitagliptin on cardiorespiratory fitness in type 2 diabetes mellitus and heart failure with reduced ejection fraction: The CANA‐HF study

2020 ◽  
Vol 36 (8) ◽  
Author(s):  
Salvatore Carbone ◽  
Hayley E. Billingsley ◽  
Justin M. Canada ◽  
Edoardo Bressi ◽  
Brando Rotelli ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Ejection Fraction ◽  
Cardiorespiratory Fitness ◽  
Reduced Ejection Fraction

Effect of Canagliflozin Compared to Sitagliptin on Serum Lipids in Patients with Type 2 Diabetes Mellitus and Heart Failure with Reduced Ejection Fraction

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Dave L. Dixon ◽  
Hayley E. Billingsley ◽  
Justin M. Canada ◽  
Cory Trankle ◽  
Dinesh Kadariya ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Ejection Fraction ◽  
Serum Lipids ◽  
Reduced Ejection Fraction

scholarly journals Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus

Circulation ◽  
2019 ◽  
Vol 139 (22) ◽  
pp. 2591-2593 ◽  
Author(s):  
Gemma A. Figtree ◽  
Karin Rådholm ◽  
Terrance D. Barrett ◽  
Vlado Perkovic ◽  
Kenneth W. Mahaffey ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction

scholarly journals Patients characteristics and prognostic implications of type 2 diabetes mellitus in heart failure with preserved, mid-rang reduced and reduced ejection fraction

2021 ◽  
Vol 72 (1) ◽  
pp. 18-24
Author(s):  
Marija Mrvošević ◽  
Marija Polovina
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction ◽  
One Year ◽  
Unique Predictor ◽  
The Impact

Introduction: Type 2 diabetes mellitus (T2DM) is frequent in patients with heart failure (HF) and correlated with an increased morbidity and mortality. The features and outcomes of patients with and without T2DM, depending on the HF type (HF with preserved: HFpEF, mid-range: HFmrEF; and reduced ejection fraction: HFrEF), are inefficiently explored. Aim: To explore the impact of T2DM on clinical features and one-year overall mortality in patients with HFrEF, HFmrEF and HFpEF. Material and methods: A prospective, observational study was conducted, including patients with HF at the Department of Cardiology, Clinical Center of Serbia, Belgrade. The enrolment occurred between November 2018 and January 2019. The study outcome was one-year all-cause mortality. Results: Study included 242 patients (mean-age, 71 ± 13 years, men 57%). T2DM was present in 31% of patients. The proportion of T2DM was similar amid patients with HFrEF, HFmrEF, and HFpEF. Regardless of the HF type, patients with T2DM were probably older and had a higher prevalence of myocardial infarction, other types of coronary disorder or peripheral arterial disorder (all p < 0.001). Also, chronic kidney disease was more prevalent in T2DM (p < 0.001). In HFpEF, T2DM patients were commonly female, and usually had hypertension and atrial fibrillation (all p < 0.001). Estimated one-year total mortality rates were significantly higher in T2DM patients. It also emerged as a unique predictor of higher mortality in HFrEF (HR; 1.33; 95% CI; 1.34 - 2.00), HFmrEF (HR; 1.13; 95% CI; 1.0 - 1.24) and HFpEF (HR; 1.21; 95% CI; 1.09 - 1.56), all p < 0.05. Conclusion: Compared with non-diabetics, patients with HF and T2DM are older, with higher prevalence of comorbidities and greater one-year mortality, regardless of HF type. Heart failure is a unique predictor of mortality in all HF types in multivariate analysis. Considering the increased risk, T2DM requires meticulous screening/diagnosis and contemporary treatment to improve outcomes.

scholarly journals COMBINATION THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND HEART FAILURE WITH REDUCED EJECTION FRACTION

2021 ◽  
Vol 39 (Supplement 1) ◽  
pp. e40
Author(s):  
Mihnea-Alexandr Gaman ◽  
Elena Codruta Dobrica ◽  
Matei Alexandru Cozma ◽  
Camelia Cristina Diaconu
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Combination Therapy ◽  
Ejection Fraction ◽  
Reduced Ejection Fraction
Sign in / Sign up

Export Citation Format

Share Document